Christine Fitzpatrick, MD
Neurology · Brooklyn, NYNPI 1750381356
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novartis at 22.8% of the total. That places this record below the midpoint for neurology clinicians in NY, where the typical reported total is $913.
Across 8 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$42
- Sunovion Pharmaceuticals Inc.$33
- Boston Scientific$23
- Acadia Pharmaceuticals Inc$23
- Avanir Pharmaceuticals, Inc.$23
- Biogen$22
- plus $16 from 1 others
What the payments were for
- Food & beverage$182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 1 | $33 |
| Boston Scientific | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Biogen | 1 | $22 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$182 in reported general payments places this provider in the 30th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality SyringeGalcanezumab-Gnlm | 13 | $23,132 |
| Memantine Hcl | 366 | $2,854 |
| Memantine Hcl ErMemantine Hcl | 20 | $2,417 |
| Pregabalin | 15 | $1,217 |
| RivastigmineRivastigmine Tartrate | 26 | $1,002 |
| Levetiracetam | 68 | $728 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $487 |
| Donepezil Hcl | 52 | $428 |
| Quetiapine Fumarate | 50 | $322 |
| Sumatriptan Succinate | 17 | $284 |
| Gabapentin | 43 | $230 |
| Carbamazepine | 22 | $167 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $95 |
| Topiramate | 22 | $79 |
| Amitriptyline Hcl | 21 | $73 |
Paid to pharmacies, not to this prescriber.
Other neurology in Brooklyn
- Idan SharonBrooklyn$2.1M
- Karen Blitz ShabbirBrooklyn$220K
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.